ĐÁNH GIÁ BƯỚC ĐẦU HIỆU QUẢ TIÊM DƯỚI KẾT MẠC BEVACIZUMAB TRONG ĐIỀU TRỊ MỘNG TÁI PHÁT

Abstract

Purpose: The aim of this study was to evaluate the efficacy and safety of subconjunctival Bevacizumab injections in patients with recurrent pterygia for preventing pterygium progression and reducing subjective symptoms. Methods: A prospective case series included 10 eyes of 10 patients with recurrent pterygia. Each eye received 3 does of subconjunctival Bevacizumab (2,5mg/0,1ml) at two-week intervals. All patients were followed up for 3 months after the first injection to evaluate changes in pterygium size and vascular. Epidemiological characteristics were collected using a structured questionnaire. Visual acuity was assessed with a Snellen chart, and intraocular pressure was measured by tonometry before and after treatment. Pterygium size and vascular changes were analyzed using ImageJ software based on images captured with a slit-lamp biomicroscope integrated with a digital camera. Results: Pterygium size and vascularity progressively decreased after each injection and significantly decreased at three months. The pterygium head area decreased from 5,85 ± 2,85 mm² to 2,95 ± 2,03 mm² (a reduction of 63,55 ± 24,50%, p = 0.005), the pterygium head length decreased from 1,84 ± 0,50 mm to 0,96 ± 0,56 mm (a reduction of 43,16 ± 25,51%, p = 0,005); the vascular density of the pterygium decreased from 19,99 ± 5,10% to 5,99 ± 2,55% (a reduction of 70,02 ± 11,17%, p = 0,005); and the vessel diameter of the pterygium decreased from 7,36 ± 0,79 pixels to 5,37 ± 0,99 pixels (a reduction of 27,31 ± 8,26%, p = 0,005). Undesirable side effects included subconjunctival hemorrhage (10%) and localized pain (10%), with no systemic complications observed. Conclusion: Short-term outcomes indicate that subconjunctival Bevacizumab injection is an effective and safe method for preventing the progression of recurrent pterygium.